|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
- GP - Locum
- NHS 111 and Out of hours providers
- GP Practices
- Primary Care Networks
|
| Title: |
|
Commencement of a Palivizumab Passive Immunisation Programme Against Respiratory Syncytial Virus (RSV) in At Risk Infants in England, Scotland and Wales
|
| Broadcast content: |
|
Following an observed sustained rise in rates of respiratory syncytial virus (RSV) infection, acute trusts / health boards in England, Scotland and Wales are asked to immediately offer a programme of monthly doses of palivizumab,
administered as a intramuscular injection, for a period of up to 7 months to
provide protection against respiratory syncytial virus (RSV) for at risk infants
as defined in the green book.
|